Tigris Pharmaceuticals

About:

Tigris Pharmaceuticals is a biopharmaceutical company developing therapeutic technologies for cancer and other unmet medical needs.

Website: http://www.tigrispharma.com

Top Investors: Wexford Capital, NGN Capital, Riverbank Capital Securities, Sonostar Capital Partners

Description:

Tigris Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic technologies for oncology and other areas of unmet medical need. Its products include Aminoflavone that is for the treatment of renal cell, breast, and lung cancer; GGTI-2418, a synthetic peptidomimetic inhibitor of geranylgeranyltransferase, which is for the treatment of lung, breast, pancreatic, and ovarian cancer; GFB-204, a calixarene derivative that is a potent and selective inhibitor of VEGFR and PDGFR tyrosine phosphorylation, which is for the treatment of prostate, pancreas, lung, breast, and renal cell. The company was founded in 2005 and is based in Bonita Springs, Florida.